GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique ...
Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine ...
The final diagnoses of the patients with normal TABs were polymyalgia rheumatica (two patients), prostate carcinoma, headache with postherpetic neuralgia ... indicating that glucocorticoid treatment ...